They monetize what they can and get the money into insiders pockets before the doors are mercifully shut.
Worst track record for longest period of time, ever.
"That is Paul Porter - the scarce skill resource". This is a joke, right? He was hailed as the second coming, and flopped. Besides, why would an honest person still be around and still let his name be associated with this travesty? Probably long gone. Like Arnie, RJ..........
Makerbok merger was one of the worst decisions ever, and Brooklyn NY? You have to be kidding. There were probably tax advantages, but you have to have income for that to be useful. Hundreds of millions in write downs, and a raft of directors and officers came with it that add to the expense side. Seven of the nine board members looking to be reinstated brought this about (two independent candidates appear not to have played a role). No accountability for insiders. Send a message, seven ""no" votes..
Go back a few years and you will see there were about a dozen frequent posters pumping this stock like mad,
then suddenly they all dried up and went away because they said they did not want to hear the doubters, but in reality it was just a couple of people with multi aliases. The whole thing has been a scam, and to answer your question, this ended a long time ago. So figure out whether to sell it and take the tax credit, or keep it and try to document that it is worthless. JMO.
1.1B shares. Does anyone doubt there will be an oversized reverse split? For those not protected from dilution (everybody here) it will race back down to pennies, a short bonanza. And oh, that $.25 floor some people imagine? What is the weighted average price he will pay for the shares (8 cents, 15 cents then 25 cents) and he does not have to buy from us and push the price up........we are providing his new shares through dilution.
This is not a great deal for outsiders.
They never give any details on the orders, for a good reason; they aren't worth squat, and management does not to want to be held accountable. Ever.
It seems to me this is a one trick pony, one false step and its over. That is okay, but the musical chairs at the top says a lot. There is a management and BoD issue, and therefore as a publicly held company, reasonable doubt about who is looking after shareholder value. Outside shareholder value. Need to rethink risk/reward.
If it is not at absolute minimum 20/1 mid term, time to bail.
Stemcells has just one thing going for it, for 24 years it has used the name Stemcells to attract naive investors, there is one born every minute. Over the that lifetime as a publicly held company, it has never produced a drug to market but has paid several CEO's and others very big money for failing. It is an historic joke.
One of the worst biotechs for outside investors. RIP OFF.
These idiots prematurely declared a reverse split with no rising fundamentals, in order to attract institutional investors, in total disregard of outside shareholders' best interests, this being a publicly held company. The BoD is to blame. Outside holders have as of now lost more than 50% of their money. Where are the institutional investors? Amateur night in Israel. Or worse. Might as well be a Chinese rip off or a Canadian mining company scam at this point. So the new CEO owns a lot of shares. So what. If they crash (as they have) the insiders will just issue themselves new subscription rights and the rest of us are washed out.
Here is the problem. The shareprice has dropped 50% from the R/S price, and that is a fact. I would call it a crash, and the institutional investors have not shown up. It was a dead stupid idea at least for outside holders'
sake. As of today, you lost half of your money as a result. Who is responsible, who is accountable? And where are the wise cracking blind pumpers that thought it was a great idea and shareholder value would go up? Gone or changed their alias. Stupid.
stock-bouncer. Agreed. I bought Biogen at $7 a long time ago and it has split several times today worth
$278 (I sold before that). My point is that Biogen has focused in on ALS and is looking at acquisitions
in general due to the current price advantages in the Bio sector. If or when BCLI has a proven answer,
it will be swept up in a heartbeat by somebody. In other words, today's price collapse on top of steadily declining value from the r/s suggests Brainstorm has not made the cut, and the shareholders are holding the bag. Maybe this will turn around, but the r/s did not attract institutional investors or any buyout interest. We just
have less shares at a lower value.
Feuers' article was a downer for sure, the CC really did not eviscerate the points he made but it was an unusual Q&A most of the "questions" were heartfelt anecdotal statements of support from people who had benefited from the procedure in some way. That is not going to do it, in any event, the shareprice dropped. Crashed, really. That reverse split was a very bad idea at the wrong time, lost almost half the value from the r/s price. Shareholders have been smacked hard.
Of course it is year end bonus time, and the "independent" compensation committee is hard at work adding up
all those hard earned performance bonuses and options so they can advise the full board on how much dilution will be required.
Well at best, whoever wrote the "embargo" notice is a neophyte, the company needs to explain that in detail rather than just confuse everyone but insiders.....or maybe they are confused as well.
That is good information, but how certain are you this "embargo" is related to a biotech conference? If material information is being withheld from shareholders who were previously notified of a conference in December, that looks like a conflict of interest, What is the priority? Guess we will find out in January.